Capricor Therapeutics price target raised to $63 from $50 at B. Riley

B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $63 from $50 and keeps a Buy rating on the shares. Following Q1 results and updated Phase 3 HOPE-3 data presented at MDA, confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 PDUFA, with shares expected to build into the decision as investors digest the expanded cardiac and functional dataset, the analyst tells investors in a research note. Despite strong recent stock performance, upside potential remains supported by multi-billion peak revenue prospects, growing partner optimism from Nippon Shinyaku, and durable demand dynamics tied to lifelong treatment and meaningful survival benefit implications, the firm says.